Furthermore, blood-based biomarkers, such as carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA), have also demonstrated promise as non-invasive screening modalities for CRC. The gene discussed is CEACAM5; the disease is neoplasm.